SUCCESSFUL TENDER OFFER FOR CEGID GROUP PROVIDES CLAUDIUS

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SUCCESSFUL TENDER OFFER FOR CEGID GROUP PROVIDES CLAUDIUS WITH MAJORITY OF SHARES
  • The consortium composed of Silver Lake and AltaOne Capital holds 88.92% of Cegid Group
  • Subsequent tender offer for remaining shares to run from September 23rd to October 6th 2016

PARIS, Sept. 20, 2016 (GLOBE NEWSWIRE) -- The AMF published on September 15, 2016, the results of the tender offer initiated by Claudius France on Cegid Group to acquire (i) all of the Cegid Group shares at the price of 61.00 euros per share (ex-dividend, following payment of 1.25 euros dividend per share on May 13, 2016) and (ii) all the redeemable warrants 1 and 2 issued by Cegid Group and traded on Euronext Paris at a price of 44.25 euros per redeemable warrant, with both shares and redeemable warrants to be paid exclusively in cash (the " Offer ").

Following such announcement, Claudius France confirms the success of its Offer. Given the 4,739,649 shares tendered to the Offer and the 3,470,156 shares acquired by Claudius Finance on July 8, 2016, Claudius France will hold, together with Claudius Finance, after the settlement-delivery expected to occur on September 21, 2016, 8,209,805 shares representing 88.92% of the share capital and 87.94% of the voting rights of Cegid Group and, taking into account the 136,807 treasury shares held by Cegid Group, 90.40% of the share capital and 89.41% of the voting rights of Cegid Group 1 . Besides, in the context of the Offer, Claudius France has acquired 25,717 redeemable warrants representing 89.47% of the outstanding redeemable warrants.

Subsequent tender offer to be open between September 23 and October 6, 2016

In order to enable Cegid Group security holders who have not yet tendered their securities to benefit from the Offer and in accordance with article 232-4 of the General Regulation of the AMF, the Offer will be reopened between September 23 and October 6, 2016.

The terms of the subsequent offer remain the same as those listed in the tender offer prospectus related to the Offer, which has received AMF visa n°13-346 on July 26, 2016.

If, immediately following the Offer, the minority shareholders do not hold more than 5% of the share capital or voting rights, Claudius France will request the implementation of a squeeze-out (the " Squeeze-Out ") in accordance with article 237-14 of the AMF's General Regulation, and the price to be paid by Claudius France for each share and each redeemable warrant tendered into the Offer (including the reopened offer) or transferred in the Squeeze-Out shall be increased by 1.25 euros, thus resulting in a price per share being equal, in total, to 62.25 euros and a price per redeemable warrant being equal, in total, to 45.50 euros.

The tender offer prospectus cleared by the AMF is available for consultation on the website of the AMF ( www.amf-france.org ) and of Cegid Group ( www.cegid.com ) .

About Cegid

Cegid is a leading player in the digital transformation of companies, providing cloud services and enterprise software to private companies and public entities alike. Cegid addresses the management needs of companies and public entities of all sizes in the fields of finance, taxation and human resources, and offers industry-specific solutions to companies in the manufacturing, trade, services and retail sectors as well as to the accounting profession. Based on MoBiClo TM , its technological concept combining Mobility, Business Intelligence and the Cloud, Cegid's innovation strategy integrates the new ways in which people use software. Cegid is an international group with more than 2,200 employees, 30 locations in France, and over 15 subsidiaries and offices worldwide. Cegid serves more than 135,000 client sites and 430,000 users, including over 150,000 in SaaS mode. In 2015, its revenues exceeded €300 million on a pro forma basis. Cegid is listed on Euronext Paris. Please visit www.cegid.com .

About Claudius

Claudius France is a holding company controlled by Claudius Finance, which is itself indirectly controlled by U.S. investment fund Silver Lake and AltaOne Capital, an investment company based in London. Claudius France has filed a tender offer for all Cegid shares and redeemable warrants. Claudius Finance is the entity that has acquired a  37.6 % stake in Cegid from Groupama, Groupama Gan Vie and I.C.M.I. on July 8, 2016..

About Silver Lake

Silver Lake is the global leader in technology investing, with over $24 billion in combined assets under management and committed capital. The firm's portfolio of investments collectively generates more than $100 billion of revenue annually and employs more than 245,000 people globally. Silver Lake has a team of approximately 100 investment and value creation professionals located in New York, Menlo Park, San Mateo, London, Hong Kong and Tokyo. The firm's current portfolio includes leading technology and technology-enabled businesses such as Alibaba Group, Ancestry, Avaya, Broadcom Limited, Cast & Crew, Ctrip, Dell, Global Blue, GoDaddy, Intelsat, Motorola Solutions, Quorum Business Solutions, Red Ventures, Sabre, Smart Modular, Solar Winds, Symantec, Vantage Data Centers, and WME/IMG. For more information about Silver Lake and its entire portfolio, please visit www.silverlake.com .

About AltaOne Capital

AltaOne is an investment firm based in London and founded in 2015 by Behdad Alizadeh and Shahriar Tadjbakhsh. AltaOne's investment strategy includes acquiring significant ownership stakes in a small number of European companies that are leaders in their markets, and in which it can enhance the long term value of their businesses as an active professional shareholder. AltaOne's principals have substantial public and private company investment experience as anchor shareholders across a broad range of industries, including technology, media and telecommunications.

Any additional information regarding the Offer may be obtained from Georgeson, acting as information agent for Claudius France, by calling the following toll-free number between 23 rd September and 6 th October:

    00 800 6540 6540

Contacts  : Brunswick - Benoit Grange Tel : + 33 1 53 96 83 83 Email : bgrange@brunswickgroup.com

Havas Worldwide Paris - Charles Fleming Tel : +33 1 58 47 94 40 Email  : charles.fleming@havasww.com

Access to the Information Memorandum and to every document relating to the Offer might be subject to legal restrictions in certain jurisdictions. Failure to comply with legal restrictions may constitute a violation of applicable laws and regulations regarding stock markets in certain jurisdictions. Claudius France declines all responsibility in case of violation by any person of applicable regulations.

Shareholders and other investors are recommended to inspect the documents relating to the Offer before taking any decision relating to the Offer.

This announcement is not an offer to purchase or a solicitation of an offer to sell any securities. The Offer will be made only pursuant to the offer documentation which will contain the full terms and conditions of the Offer. Any decision in respect of the Offer should be made only on the basis of the information contained in such offer documentation. The Offer relates to the shares of a French company and is subject to French procedural and disclosure requirements that are different from those of other jurisdictions, including the United States. In addition, Claudius France, its direct or indirect shareholders and their respective affiliates may purchase or arrange to purchase shares of Cegid Group otherwise than pursuant to the Offer, such as in open market or privately negotiated purchases.

1  As of September 13, 2016, the share capital of Cegid Group was comprised of 9,233,057 shares and 9,335,162 voting rights, in accordance with article 223-11 of the AMF's General Regulation.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 31

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 655

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 406

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 83

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 18

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 55

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

VivoPower Innovates with XRP-Focused Treasury Strategy

Updated Category News Views 359

VivoPower's Transformational XRP Strategy VivoPower International PLC (NASDAQ: VVPR) has recently embarked on a groundbreaking journey by announcing a new strategy centered on the digital asset XRP. The company is positioning itself as the first publicly traded entity to implement an XRP-focused digital asset treasury. This innovative approach is not only exciting for...

Continue Reading
Recognizing Excellence in Product Stewardship for 2024

Updated Category News Views 114

Celebrating Product Stewardship Excellence The Product Stewardship Society has announced a significant honor for 2024—Lynn L. Bergeson has been named the recipient of the prestigious Allan K. Fleeger Distinguished Service Award. This esteemed award has been established to acknowledge the remarkable contributions of individual product stewards who have played crucial...

Continue Reading
Gold Hits New Heights Amid Tensions and Election Uncertainty

Updated Category News Views 163

Gold Prices Surge to Record Heights In recent trading, gold prices have reached unprecedented levels, reflecting a significant rise driven by various factors, including political uncertainties and ongoing international conflicts. As anticipation surrounding a highly competitive U.S. presidential election grows, along with persistent tensions in regions such as the Middle...

Continue Reading
Paul Jebely Joins Sterlington as Aviation Law Vice Chair

Updated Category News Views 257

Paul Jebely Joins Sterlington as New Partner Sterlington PLLC is excited to announce that Paul Jebely has joined the firm as their new Partner and Vice Chair of International, marking a crucial advancement in their aviation law practice. Jebely is not just any attorney; he is a globally recognized authority in private aviation law, especially known for his work with...

Continue Reading
William James Wartinbee III Executes Significant Sell Strategy

Updated Category News Views 62

William James Wartinbee III Implements Key Sell Strategy In a noteworthy insider sale, William James Wartinbee III, the Executive Vice President at Gartner (IT), has sold 210 shares of the company. This transaction was documented in a Form 4 filing with the U.S. Securities and Exchange Commission, and the sale was valued at about $103,275. Examining Gartner's Current...

Continue Reading